Latin America Cancer Chemotherapy Market Outlook (2021–2031)

Synergistic Approaches: Surgery, Radiation, and Targeted Treatments

A key driver of the Latin America cancer chemotherapy market is the increasing adoption of multimodal treatment strategies. Chemotherapy is widely used in the neoadjuvant setting to shrink tumors before surgery and as adjuvant therapy to eliminate residual disease across breast, colorectal, and lung cancers. It also serves as a radiosensitizer, improving outcomes in locally advanced tumors when combined with radiation therapy. These integrated approaches are increasingly reflected in clinical guidelines across major oncology centers in Brazil, Mexico, and Argentina.

Simultaneously, chemotherapy maintains its role in combination with targeted therapies and immunotherapies, which are being introduced more frequently as payers expand oncology coverage. While targeted agents often command higher prices, chemotherapy's relative affordability and broad applicability support its continued usage in first‑line and later‑line settings. These trends create opportunities for chemotherapy utilization, particularly as cancer care becomes multidisciplinary and evidence‑based across the region.

Machine Learning in Personalized Chemotherapy and Dose Planning

Artificial Intelligence (AI) enables personalized regimen design and optimized dosing strategies. AI tools can integrate clinical data, genetic profiles, imaging, and treatment response information to support individualized therapy plans that maximize efficacy and minimize toxicity. In major oncology hubs such as São Paulo, Mexico City, and Buenos Aires, digital health initiatives and electronic health record systems are facilitating early exploration of AI‑assisted decision support.

By enhancing predictive analytics for treatment response and toxicity risk, AI can help clinicians tailor chemotherapy choices and dosing schedules more precisely, especially in complex cases. AI also accelerates real‑world evidence generation and optimizes clinical trial design, making it easier to identify patient subgroups likely to benefit from specific chemotherapy combinations. As digital infrastructure matures and data sharing expands, AI has the potential to improve clinical outcomes and treatment efficiency.

The "Latin America Cancer Chemotherapy Market Size and Forecast (2025–2031)" report provides a detailed analysis of the market covering below areas:

• Latin America Cancer Chemotherapy market size and forecast at regional and country levels for all the key market segments covered under the scope
• Latin America Cancer Chemotherapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Latin America Cancer Chemotherapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Latin America Cancer Chemotherapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Latin America Cancer Chemotherapy market report is divided into Mexico, Brazil, Argentina, Peru, Chile, and Colombia. Brazil held the largest share in 2024.

Brazil is the largest chemotherapy market in the region, supported by the country's extensive public healthcare system (SUS) and strong local pharmaceutical manufacturing. Universal coverage facilitates broad access to essential chemotherapy drugs, while private oncology services expand advanced regimen utilization. The country also participates in regional clinical research and has a growing infrastructure for treatment delivery and early diagnosis.

Mexico follows closely, with public institutions and private providers delivering chemotherapy across urban and semi‑urban centers. Payer reforms and enhanced public financing have improved drug availability, although rural access remains uneven. Mexico's oncology programs emphasize early detection and combination treatment protocols, and partnerships with multinational pharmaceutical firms broaden access to both traditional and novel therapies.

Argentina exhibits robust demand for chemotherapy due to high cancer incidence and improving public oncology services. Regional collaborations and healthcare reforms support access, though economic volatility can affect supply chains and pricing. Colombia and Chile show steady growth, with growing investment in oncology infrastructure, reimbursement policies, and expanded use of outpatient infusion services, particularly in urban centers.

• The report includes qualitative and quantitative data in the Latin America Cancer Chemotherapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Latin America Cancer Chemotherapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Latin America Cancer Chemotherapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Latin America Cancer Chemotherapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover Latin America Cancer Chemotherapy market segments by therapy type, indication, distribution channel, and geography across Mexico, Brazil, Argentina, Peru, Chile, and Colombia. They cover the market revenue forecast and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Latin America Cancer Chemotherapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Latin America Cancer Chemotherapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Latin America cancer chemotherapy market are:

• In August 2025, Civica Rx expanded partnerships with hospitals in Argentina to ensure a steady supply of essential chemotherapy drugs, responding to ongoing challenges of oncology drug shortages in the region.
• In May 2025, PharmaMar and Adium Pharma's subsidiary, Raffo, obtained marketing authorization in Argentina for Zepzelca (lurbinectedin) for adult patients with metastatic small cell lung cancer who progressed after platinum-based chemotherapy, expanding post-chemotherapy treatment options.